ELVN
Enliven TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Primary-source guidance still supports a live de-risking path in 2026: additional ENABLE data, FDA alignment, and planned ENABLE-2 initiation, while cash of about $462.6 million was said to fund operations into 1H29 [#PR-2026-03-03] [#10-K-2026-03-03].
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +4.2.
What can break
Despite runway into 1H29, the company remains pre-revenue and long-term value still depends on future clinical success and capital access.
Momentum
93
Value
41
Sentiment
20
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $38.00 · Bull $58.00 · Bear $24.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $65.00
Why
Momentum93 · Δ7d +4.2
Value41 · Δ7d -0.1
Sentiment20 · Δ7d -4.9
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
93
26% active weight
Current posture
7d trendImproving
Δ7d
+4.2
Δ21d
+7.0
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
20
34% active weight
Current posture
7d trendSoftening
Δ7d
-4.9
Δ21d
-5.7
Why this grade
Composite grade D. Momentum 93.5 / Value 41.1 / Sentiment 19.5
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$3.8B
Beta
0.33
Shares Out
71.44M
P/E (TTM) · Derived
-29.1
P/S (TTM)
-
P/FCF (TTM) · Derived
-48.12
Rev YoY
-
EPS YoY
-34.0%
Gross Margin
-
Op Margin
-
Net Debt
-$462.22M
Current Ratio
40.32
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology